- Home
- ADVM vs CUE Comparison
ADVM vs CUE Comparison
Compare ADVM & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- CUE
- Stock Information
- Founded
- ADVM 2006
- CUE 2014
- Country
- ADVM United States
- CUE United States
- Employees
- ADVM N/A
- CUE N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- CUE Health Care
- Exchange
- ADVM Nasdaq
- CUE Nasdaq
- Market Cap
- ADVM 47.4M
- CUE 52.8M
- IPO Year
- ADVM 2014
- CUE 2018
- Fundamental
- Price
- ADVM $2.74
- CUE $0.90
- Analyst Decision
- ADVM Strong Buy
- CUE Strong Buy
- Analyst Count
- ADVM 5
- CUE 3
- Target Price
- ADVM $23.80
- CUE $3.00
- AVG Volume (30 Days)
- ADVM 297.2K
- CUE 644.9K
- Earning Date
- ADVM 08-11-2025
- CUE 08-13-2025
- Dividend Yield
- ADVM N/A
- CUE N/A
- EPS Growth
- ADVM N/A
- CUE N/A
- EPS
- ADVM N/A
- CUE N/A
- Revenue
- ADVM $1,000,000.00
- CUE $7,991,000.00
- Revenue This Year
- ADVM N/A
- CUE N/A
- Revenue Next Year
- ADVM $18.82
- CUE $23.84
- P/E Ratio
- ADVM N/A
- CUE N/A
- Revenue Growth
- ADVM N/A
- CUE 13.83
- 52 Week Low
- ADVM $1.78
- CUE $0.45
- 52 Week High
- ADVM $10.14
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ADVM 59.62
- CUE 61.83
- Support Level
- ADVM $2.50
- CUE $0.71
- Resistance Level
- ADVM $2.75
- CUE $1.03
- Average True Range (ATR)
- ADVM 0.20
- CUE 0.08
- MACD
- ADVM 0.06
- CUE 0.01
- Stochastic Oscillator
- ADVM 82.50
- CUE 52.42
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.